Table I.

Incidence of anti-panitumumab Abs and panitumumab-neutralizing Abs in clinical studies

Subjects Developing Non-Transient Anti-Panitumumab AbsaSubjects Testing Neutralizing Ab Positive Postdose
 Positive subjects21
 Total subjects612612
 % Positive0.30.2
 Positive subjects258
 Total subjects604604
 % Positive4.11.3
  • a Subject tests positive postdose and remains positive at the final time point tested. Postdose positive subjects testing positive predose are excluded.